Advertisement

Clinical Management of Soft Tissue Sarcomas

  • J. Treuner
  • M. Morgan
Chapter
Part of the Current Topics in Pathology book series (CT PATHOLOGY, volume 89)

Abstract

The histological heterogeneity and the variable clinical manifestations of malignant soft tissue tumours calls for a variable therapeutic approach. The essential strategy for treatment is based on a number of factors: histology, site, tumour size, local invasiveness, systemic spread and the age at diagnosis. The tumour characteristics at diagnosis are to a certain extent interrelated and not entirely independent of one another, e.g., tumour size and primary site, tumour invasiveness and histology which is also related to site and age. In addition to the tumour characteristics, there are a number of important prognostic factors which influence the type of therapy and the outcome. The dynamic prognostic factors take into account the individual chemo- and radiosensitivity of the tumour, the physical and the psychological tolerance to treatment as well as the quality of the diagnostic procedure and the treatment. The aim of therapy in each case is to ensure a relapse-free survival and avoid mutilating surgery or loss of function of a part of the body. This goal can be achieved in many situations but not in all. The potential threat of the cancer has always priority over the functional, cosmetic aspects.

Keywords

Soft Tissue Sarcoma Synovial Sarcoma Malignant Fibrous Histiocytoma Epithelioid Sarcoma Clear Cell Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baum ES et al. (1981) Phase II study in cisdichlorodiamine-platinum in refactory childhood cancer: Children’s Cancer Study Group Report. Cancer Treat Rep 65: 815–822PubMedGoogle Scholar
  2. Crist WM et al. (1987) Intensive chemotherapy including cisplatin with or without etoposide for children with soft tissue sarcoma. Med Pediatr Oncol 15: 51–57PubMedCrossRefGoogle Scholar
  3. Emminger W, Emminger-Schmidmeier W (1991) High dose melphalan, etoposide ± carboplatin (MEC) combined with 12-gray fractionated total-body irradiation in children with generalized solid tumors. Pediatr Hematol Oncol 8: 13–22PubMedCrossRefGoogle Scholar
  4. Ghavimi F et al. (1981) Multidisciplinary treatment of embryonal rhabdomyosarcoma in children: a progress report. Natl Cancer Inst Monogr 56: 111–120PubMedGoogle Scholar
  5. Kingston JE, Mc Elwain TJ, Malpas JS (1983) Childhood rhabdomyosarcoma: experience of Children’s Solid Tumour Group ( CSTG ). Br J Cancer 48: 195–207CrossRefGoogle Scholar
  6. Maurer HM et al. (1978) The intergroup rhabdomyosarcoma study. Natl Cancer Inst Monogr 56: 61–68Google Scholar
  7. Miser J (1990) Autologous bone marrow transplantation for the treatment of sarcomas. In: Johnson FL, Pochedly C (eds) Bone marrow transplantation in children. Greenwood, New York, pp 289–298Google Scholar
  8. Treuner J, Koscielniak E, Keim M (1989) Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother Pharmacol 24: 48–50CrossRefGoogle Scholar
  9. Treuner J, Flamant F, Carli M (1991) Results of treatment of rhabdomyosarcoma in the European Studies. In: Maurer, Ruymann, Pochedly (eds) Rhabdomyosarcoma and related tumors in children and adolescents. CRC Press, Boca Raton, pp 227–241Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • J. Treuner
  • M. Morgan

There are no affiliations available

Personalised recommendations